Market Size in 2024 | Market Forecast in 2034 | CAGR (in %) | Base Year |
---|---|---|---|
USD 40.52 Billion | USD 62.33 Billion | 4.4% | 2024 |
The global pharmaceutical solid dosage contract manufacturing market size was worth around USD 40.52 Billion in 2024 and is predicted to grow to around USD 62.33 Billion by 2034 with a compound annual growth rate (CAGR) of roughly 4.4% between 2025 and 2034. The report analyzes the global pharmaceutical solid dosage contract manufacturing market's drivers, restraints/challenges, and the effect they have on the demands during the projection period. In addition, the report explores emerging opportunities in the pharmaceutical solid dosage contract manufacturing industry.
The market report offers quantitative and qualitative insights into the key drivers, opportunities, constraints, and challenges impacting global pharmaceutical solid dosage contract manufacturing industry growth.
Pharmaceutical solid dosage forms are commonly used drug delivery methods across patient groups. Pharmaceuticals solid dosage contract manufacturing is dominating pharmaceutical formulations due to rising popularity and an increase in the adoption rate by pharmaceutical companies. The solid dosage formations are manufactured and are available in variants such as capsules, tablets, lozenges, etc.
The Pharmaceutical manufacturing unit is looking forward to outsourcing drug formulation, i.e., Contract Manufacturing Organization. A contract manufacturing organization (CMO) is an organization that serves the pharmaceutical industry and provides clients with comprehensive services, from drug development to manufacturing. Outsourcing to a CMO allows pharmaceutical clients to expand their technical resources, without the increased overhead and achieve economies of scale.
Increase in importance and investment toward healthcare drive the growth of the market
The pharmaceutical solid dosage provides improved efficiency and minimized cost of drug formulation, which is boosting the global pharmaceutical solid dosage contract manufacturing market growth. CMO (contract Manufacturing Outsourcing) will be beneficial for pharmaceutical companies due to the growing capital-intensive nature of the business as CMO will ensure business continuity and risk mitigation. Rising popularity, advanced technology, and increased governmental support are driving the pharmaceutical solid dosage contract manufacturing market globally.
Covid-19 has impacted the healthcare sector positively by shifting the focus of people toward the importance of healthcare. Government’s initiative to provide effective treatment to patients suffering from infection has proved to be a recreation of medical priorities across healthcare institutions. This will result in the growth of the Pharmaceutical Solid Dosage Contract Manufacturing market in the next coming years.
Prevalence of regulatory issues and supply chain disruptions might hinder the growth of the market
Potential restraints in the pharmaceutical solid dosage contract manufacturing industry include regulatory hurdles, increasing competition, pricing pressures, supply chain disruptions, and the need for significant investments in equipment and facilities. Additionally, the increasing complexity of drug formulations and the need for specialized expertise may make it difficult for some contract manufacturers to keep up with the demands of the market.
Persistent technological advancements and rise in need for cost-effective solutions create ample opportunities for the market
The global pharmaceutical solid dosage contract manufacturing market presents several opportunities for growth. The increasing demand for personalized medicine and the need for specialized formulations has created a niche for contract manufacturers with expertise in these areas.
Additionally, the trend towards outsourcing and the need for cost-effective solutions by pharmaceutical companies provide opportunities for contract manufacturers to expand their client base. The growing importance of biologics and biosimilars in the pharmaceutical industry also presents an opportunity for contract manufacturers to develop and expand their capabilities in this area. Finally, advancements in technology, such as automation and continuous manufacturing, provide opportunities for contract manufacturers to improve efficiency and reduce costs.
Apprehensions regarding risk management with intellectual property and competitiveness of the industry might act as a challenge
The pharmaceutical solid dosage contract manufacturing industry faces several challenges. One of the main challenges is ensuring compliance with regulatory requirements, which can be time-consuming and costly. The industry is also highly competitive, and contract manufacturers must be able to provide high-quality services at competitive prices. Other challenges include maintaining a reliable supply chain, managing risks associated with intellectual property, and staying up-to-date with new technologies and industry developments. The increasing demand for flexibility and customization in manufacturing processes also poses a challenge for contract manufacturers.
The global pharmaceutical solid dosage contract manufacturing market is bifurcated into product type, drug release pattern, and region.
Based on product type, the market is bifurcated into tablets, capsules, powder, lozenge, and others. The tablets segment held the largest market share in 2024 and is further predicted to grow rapidly at a remarkable CAGR during the forecast period. This is mainly due to the increased popularity of tablets as a preferred dosage form by patients due to their ease of administration, portability, and convenience. Tablets also offer better stability and longer shelf life compared to other solid dosage forms, making them an attractive option for pharmaceutical companies. Additionally, tablets can be produced at a larger scale, allowing for cost savings through economies of scale. These factors drive the growth of the segment during the forecast period.
Based on drug release pattern, the market is segmented into instant release, sustained release, extended release, effervescent tablets, chewable tablets, and enteric release. The sustained release segment held the dominating market share in 2024 and is further predicted to cite the fastest CAGR during the forecast period. The growth of the segment is mainly due to increasing demand for medications that provide a slow and steady release of the active ingredient over an extended period. Sustained-release formulations allow for reduced dosing frequency, better patient compliance, and improved therapeutic outcomes.
By Service Type, the global pharmaceutical solid dosage contract manufacturing market is split into Formulation Development, Manufacturing, Packaging.
In terms of End-user, the global pharmaceutical solid dosage contract manufacturing market is categorized into Big Pharma, Small & Medium Pharma, Biotech Companies.
These formulations are particularly useful for chronic conditions that require continuous medication and where it may be difficult for patients to adhere to a dosing regimen. In addition, sustained-release formulations can also reduce the risk of side effects and toxicity associated with high doses of medication, as they release the active ingredient slowly over time. This has led to increased interest from pharmaceutical companies and healthcare providers in developing sustained-release formulations for a variety of therapeutic areas, including cardiovascular disease, diabetes, and pain management. These factors further drive the growth of the segment during the forecast period.
Report Attributes | Report Details |
---|---|
Report Name | Pharmaceutical Solid Dosage Contract Manufacturing Market |
Market Size in 2024 | USD 40.52 Billion |
Market Forecast in 2034 | USD 62.33 Billion |
Growth Rate | CAGR of 4.4% |
Number of Pages | 190 |
Key Companies Covered | Bemis Company Inc., Multisorb Technologies Inc., Linpac Packaging Limited, CVP Systems Inc., Sealed Air Corporation, Berry Plastics Corporation, ULMA Packaging, Orics Industries Inc., Coveris Holdings S.A., Amcor Limited, and others., and others. |
Segments Covered | By Dosage Form, By Drug Type, By Service Type, By End-user, and By Region |
Regions Covered | North America, Europe, Asia Pacific (APAC), Latin America, The Middle East and Africa (MEA) |
Base Year | 2024 |
Historical Year | 2020 to 2023 |
Forecast Year | 2025 - 2034 |
Customization Scope | Avail customized purchase options to meet your exact research needs. Request For Customization |
North America to lead the global market followed by Europe
The global pharmaceutical solid dosage contract manufacturing market is dominated by North America followed by Europe due to driving factors such as advancement in technology, improved healthcare infrastructure, and increased research & development activities in the market of pharmaceuticals. CMO has also contributed to the region’s market by investing in new technologies and facilities by introducing distributed manufacturing to take manufacturing closer to the patient and adopting continuous manufacturing & digitization of processes.
For example, CMOs are partnering with third-party vendors for layered analytics with the aim of optimizing processes, introducing preventive maintenance, and making supply chains transparent. Rising number of companies outsourcing projects in the developing economies of this region has also ensured the growth of the market. Owing to the increased initiatives by the Asia Pacific government and the adoption of advanced technologies, the pharmaceutical solid dosage contract manufacturing market will be growing rapidly in Asia Pacific in the next coming years.
The report provides a company market share analysis to give a broader overview of the key market players. In addition, the report also covers key strategic developments of the market, including acquisitions & mergers, new product launches, agreements, partnerships, collaborations & joint ventures, research & development, and regional expansion of major participants involved in the pharmaceutical solid dosage contract manufacturing market on a global and regional basis.
The global pharmaceutical solid dosage contract manufacturing market is dominated by players like:
The global pharmaceutical solid dosage contract manufacturing market is segmented as follows;
By Dosage Form
By Drug Type
By Service Type
By End-user
By Region
FrequentlyAsked Questions
Pharmaceutical solid dosage forms are commonly used drug delivery methods across patient groups. The Pharmaceutical manufacturing unit is looking forward to outsourcing drug formulation, i.e., Contract Manufacturing Organization. A contract manufacturing organization (CMO) is an organization that serves the pharmaceutical industry and provides clients with comprehensive services, from drug development to manufacturing. Outsourcing to a CMO allows pharmaceutical clients to expand their technical resources, without the increased overhead and achieve economies of scale.
The global pharmaceutical solid dosage contract manufacturing market is expected to grow due to Growing outsourcing trend in pharma and rising demand for cost-effective, scalable manufacturing support market growth.
According to a study, the global pharmaceutical solid dosage contract manufacturing market size was worth around USD 40.52 Billion in 2024 and is expected to reach USD 62.33 Billion by 2034.
The global pharmaceutical solid dosage contract manufacturing market is expected to grow at a CAGR of 4.4% during the forecast period.
North America is expected to dominate the pharmaceutical solid dosage contract manufacturing market over the forecast period.
Leading players in the global pharmaceutical solid dosage contract manufacturing market include Bemis Company Inc., Multisorb Technologies Inc., Linpac Packaging Limited, CVP Systems Inc., Sealed Air Corporation, Berry Plastics Corporation, ULMA Packaging, Orics Industries Inc., Coveris Holdings S.A., Amcor Limited, and others., among others.
RelatedNews
HappyClients
Zion Market Research
Tel: +1 (302) 444-0166
USA/Canada Toll Free No.+1 (855) 465-4651
3rd Floor,
Mrunal Paradise, Opp Maharaja Hotel,
Pimple Gurav, Pune 411061,
Maharashtra, India
Phone No +91 7768 006 007, +91 7768 006 008
US OFFICE NO +1 (302) 444-0166
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com
We have secured system to process your transaction.
Our support available to help you 24 hours a day, five days a week.
Monday - Friday: 9AM - 6PM
Saturday - Sunday: Closed